相关实验视频
Updated: Jul 15, 2026

07:59
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
在心力衰竭患者中使用β-阻塞剂,血管新生素II和ACE抑制剂
Lancet (London, England)
|November 22, 2001
概括
在接受血管增生酶转化酶 (ACE) 抑制剂的心力衰竭患者中,添加β抑制剂可显著降低血管增生酶II水平. 这表明β抑制剂可能通过降低心力衰竭中的血管新素II来增强ACE抑制剂治疗.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在心力衰竭患者中,血液中的血管素II水平升高是常见的,即使使用血管素转化酶 (ACE) 抑制剂治疗.
- 在这种情况下,β-阻断剂在调节血管激素II中的作用需要进一步研究.
研究的目的:
- 为了比较心力衰竭患者的血管素II度,这些患者接受了伴有或没有β-阻断剂的ACE抑制剂治疗.
主要方法:
- 分析了匹配的患者组.
- 在接受单独ACE抑制剂的患者和接受ACE抑制剂加β抑制剂的患者中,测量了血管新生素II的血度.
主要成果:
- 同时服用β-阻塞剂的患者与没有β-阻塞剂 (15.5 fmol/mL) 的患者相比,表现出明显较低的血管新素II度 (几何平均值1.1 fmol/mL).
- 血管激素II水平的差异在统计学上是显著的.
结论:
- 贝塔阻塞可能会降低心力衰竭患者的血管新素II水平,这些患者接受了ACE抑制剂治疗.
- 这种降低血管新素II的水平可能有助于贝塔抑制剂在心力衰竭管理中的整体治疗效益.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

